Childhood Hematopoietic Cell Transplantation (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (09/28/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Allogeneic Hematopoietic Cell Transplantation (HCT)

Added Locatelli et al. as reference 54 and level of evidence 3iiiDii. Also added Berger et al. as reference 58 and level of evidence 3iiiA.

Added Horn et al. as reference 82 and level of evidence 3iiDii.

Complications After HCT

Added Levy et al. as reference 16 and level of evidence 3iiiB.

Revised text to state that adenovirus infection is a major issue in T-cell–depleted transplantation, and monitoring by quantitative blood polymerase chain reaction followed by therapy with cidofovir or brincidofovir (awaiting U.S. Food and Drug Administration approval) has led to a major decrease in morbidity (cited Hiwarkar et al. as reference 17).

Added Jacoby et al. as reference 51 and level of evidence 3iiiA.

Late Effects After HCT in Children

Added text to state that the Children's Oncology Group has also published more specific recommendations for late effects surveillance after HCT (cited Chow et al. as reference 172).

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Current Clinical Trials

Next section >
About This PDQ Summary